• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 49
  • 43
  • 5
  • 4
  • 4
  • 2
  • 2
  • 2
  • 1
  • Tagged with
  • 121
  • 121
  • 34
  • 34
  • 28
  • 24
  • 20
  • 19
  • 14
  • 14
  • 12
  • 12
  • 11
  • 10
  • 10
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
101

Competing Mortality Contributes to Excess Mortality in Patients with Poor-Risk Lymph Node-Positive Prostate Cancer Treated with Radical Prostatectomy

Fröhner, Michael, Scholz, Albrecht, Koch, Rainer, Hakenberg, Oliver W., Baretton, Gustavo B., Wirth, Manfred P. 14 February 2014 (has links) (PDF)
Background: Factors predicting survival in men with lymph node-positive prostate cancer are still poorly defined. Patients and Methods: 193 prostate cancer patients with histopathologically proven lymph node involvement with a median follow-up of 7.3 years were studied. 94% of patients received immediate hormonal therapy. Kaplan-Meier curves were calculated to evaluate overall survival rates and compared with the log-rank test. Cumulative disease-specific and competing mortality rates were calculated by competing risk analysis and compared with the Pepe-Mori test. Cox proportional hazard models were used to determine the independent significance of predictors of all-cause mortality. Results: Age (70 years or older vs. younger), Gleason score (8–10 vs. 7 or lower) and the number of involved nodes (3 or more vs. 1–2) were identified as independent predictors of all-cause mortality. When patients with 0–1 of these risk factors were compared with those with 2–3 risk factors, all-cause (rates after 10 years 21% vs. 71%, p < 0.0001), disease-specific (12 vs. 37%, p = 0.009) and competing mortality (9 vs. 33%, p = 0.02) differed significantly. Conclusions: Some of the excess mortality in patients with poor-risk lymph node-positive prostate cancer may be attributed to increased competing mortality, possibly caused by an interaction between comorbid diseases and hormonally treated persistent or progressive prostate cancer. / Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.
102

Impacto da solução de Carnoy no número de linfonodos resgatados em peças cirúrgicas de câncer gástrico: estudo prospectivo randomizado / Impact of Carnoy\'s solution in lymph node retrieval following D2 gastrectomy for gastric cancer: prospective randomized trial

Andre Roncon Dias 25 August 2014 (has links)
Introdução: O adenocarcinoma gástrico é uma doença de elevada incidência e alta mortalidade. A gastrectomia com linfadenectomia é tratamento potencialmente curativo, promovendo controle loco-regional da doença e fornecendo material para análise histopatológica. Para o adequado estadiamento dos pacientes é recomendado que pelo menos 16 linfonodos sejam examinados pela patologia, entretanto, espera-se maior sobrevida quando >= 30 linfonodos são avaliados, mesmo em pacientes com tumores precoces. A justificativa para este achado é o sub-estadiamento de pacientes com poucos linfonodos examinados. Linfonodos pequenos são particularmente difíceis de serem encontrados, mas podem conter metástases e impactar negativamente na sobrevida. Visando facilitar sua identificação, soluções clareadoras de gordura foram propostas, entretanto não há evidência clara de seu benefício clínico. Objetivos: Comparar as soluções de Carnoy e de formalina neutra tamponada em relação ao número absoluto de linfonodos encontrados na peça cirúrgica de pacientes submetidos a gastrectomia. Averiguar se linfonodos retirados cirurgicamente são perdidos com a fixação em formalina e, caso isso ocorra, se este fato é relevante para o estadiamento. Observar se o protocolo de pesquisa influenciou o número de linfonodos encontrados. Métodos: Cinquenta produtos de gastrectomia subtotal com linfadenectomia D2 por adenocarcinoma gástrico foram randomizados para fixação em Carnoy ou formalina com posterior dissecção da peça em busca de linfonodos. Após a dissecção do grupo Formalina, a gordura residual a ser desprezada foi imersa em Carnoy e reavaliada posteriormente. Os dados de 25 gastrectomias D2 operadas previamente ao estudo também foram avaliados. Resultados: A média de linfonodos encontrados nos grupos Carnoy e Formalina foi de 50,4 e 34,8; respectivamente (p < 0,001). Na gordura residual foram encontrados linfonodos em todos os casos (média 16,9 linfonodos), elevando a média do grupo Formalina para 51,7 (valor similar ao do grupo Carnoy, p=0,809). Com exceção de 1 linfonodo de 7mm, todos os demais encontrados na gordura residual mediram <= 3mm. Treze linfonodos metastáticos passaram despercebidos com a fixação em formalina e a revisão da gordura residual determinou a mudança de estadiamento de 2 (8%) pacientes. Os linfonodos encontrados no Carnoy possuíam tamanho significativamente menor quando comparados aos do grupo Formalina (p=0,01). A média de linfonodos encontrados no grupo retrospectivo foi similar ao do grupo Formalina prospectivo (p=0,802). Conclusões: Quando comparada à formalina, a solução de Carnoy permite encontrar número maior de linfonodos no espécime cirúrgico de gastrectomias com linfadenectomia. Linfonodos milimétricos foram perdidos após a fixação em formalina, estes foram identificados com o Carnoy e são clinicamente relevantes, pois podem conter metástases modificando assim, o estádio clínico e prognóstico do paciente. A implementação de protocolo de pesquisa não influenciou o número de linfonodos encontrados neste estudo / Background: Gastric adenocarcinoma is a frequent disease with high mortality ratio. Gastrectomy with lymphadenectomy is potentially curative, allows local control of the disease and provides material for TNM classification. While pathology examination of at least 16 lymph nodes is recommended following surgery, longer survival rates are expected when >=30 lymph nodes are examined, even for early gastric cancer. The understaging of patients with less examined lymph nodes justifies this findings. Small lymph nodes are particularly difficult to identify and fat clearing solutions have been proposed to improve this, but there is no evidence of their clinical benefit. Objectives: Compare Carnoy\'s solution (CS) and formalin in terms of the total number of examined lymph nodes following gastrectomy. Verify if surgically retrieved lymph nodes are lost with the formalin fixation and if this fact is clinically significant. Observe if a research protocol influences the number of examined lymph nodes. Methods: Fifty specimens of gastrectomy with D2 lymphadenectomy were randomized for fixation in CS or formalin with posterior dissection in search for lymph nodes. In the Formalin group, the residual fat to be discarded was immersed in CS and dissected again. Data from 25 D2 gastrectomies performed previously the present study were retrospectively analyzed. Results: The medium number of examined lymph nodes was 50.4 and 34.8 for CS and formalin, respectively (p < 0.001). Lost lymph nodes were found in all cases in the Residual Fat group (medium 16.9), this increased the Formalin group average to 51.7 (which is similar to the CS group, p=0.809). With one exception (7mm), all other examined lymph nodes in the Residual Fat group measured <= 3mm. Thirteen lymph nodes from this group were metastatic, this determined the upstaging of 2 (8%) patients. Lymph nodes from the CS group were smaller than those found in the formalin group (p=0.01). The medium number of retrieved lymph nodes in the retrospective group was similar to the formalin group (p=0.802). Conclusions: When compared to formalin, Carnoy\'s solution increases lymph node detection following gastrectomy with lymphadenectomy. CS identifies small lymph nodes lost with formalin fixation and that are clinically significant, since they may contain metastasis, modifying the TNM classification. No influence of the research protocol over the number of examined lymph nodes was observed in the present study.
103

Identificação de linfonodo sentinela em cancer do colo uterino / Identification of the sentinel lymph node in cervical cancer

Vieira, Sabas Carlos 12 August 2018 (has links)
Orientador: Luiz Carlos Zeferino / Tese (doutorado) - Universidade Estadual de Campinas, Faculdade de Ciencias Medicas / Made available in DSpace on 2018-08-12T08:55:33Z (GMT). No. of bitstreams: 1 Vieira_SabasCarlos_D.pdf: 1418388 bytes, checksum: 1d70cc451697cfbd93e48319a0284d4e (MD5) Previous issue date: 2008 / Resumo: Objetivos: Avaliar a detecção do linfonodo sentinela em pacientes com câncer do colo do útero utilizando a combinação de azul patente com tecnécio99m e complicações associadas ao uso do azul patente. Sujeitos e métodos: Este foi um estudo de uma série de casos, para o qual foram selecionadas 56 mulheres com diagnóstico de câncer do colo do útero estádios Ia2,Ib1,Ib2 e IIa da FIGO, que se submeteram ao procedimento de identificação do linfonodo sentinela. O período de realização do estudo foi de maio de 2006 a dezembro de 2007. O estudo é apresentado em dois artigos: o primeiro consiste na detecção do linfonodo sentinela no câncer do colo do útero pela combinação do azul patente com tecnécio 99m e avalia a concordância entre a linfocintigrafia pré-operatória e o mapeamento linfático intra-operatório com o gama probe; o segundo consiste na avaliação das alterações da oximetria de pulso das pacientes submetidas à cirurgia após a injeção do azul patente. Resultados: No primeiro artigo identificou-se pelo menos um linfonodo sentinela em 83,13% das pacientes e a localização mais freqüente destes linfonodos foi na cadeia ilíaca externa. A sensibilidade, especificidade, valor preditivo positivo e valor preditivo negativo foram, respectivamente, 80%, 100%, 100% e 97,67% no histopatológico de congelação. Além disso, observou-se que linfocintigrafia pré operatória detecta um número consideravelmente menor de linfonodos sentinelas quando comparado ao mapeamento linfático intra-operatório com o gama probe. No segundo estudo observou-se que somente uma paciente apresentou reação anafilática. Treze pacientes apresentaram queda de oximetria de pulso (menor que 96% de saturação) após a injeção do azul patente no colo do útero, que durou em média cinco minutos e sem repercussões clínicas; essa queda se associou de forma limítrofe com tumores maiores e localizados ao redor do orifício externo do canal cervical. Conclusões: Concluiu-se que a combinação do azul patente com o tecnécio99m demonstrou excelentes resultados na detecção do linfonodo sentinela; a linfocintigrafia pré-operatória não oferece qualquer vantagem em relação ao mapeamento linfático intra-operatório com azul patente e tecnécio99m. Não houve repercussões clínicas devido à queda da oximetria de pulso e essas alterações se correlacionaram, embora com significância limítrofe, com tumores maiores e localizados ao redor do orifício cervical externo. / Abstract: Objectives: To evaluate sentinel lymph node detection in cervical cancer patients using a combination of patent blue dye and technetium99m and assess complications associated with the use of patent blue dye. Subjects and methods: This study investigated a case series that selected 56 women diagnosed with FIGO stage Ia2, Ib1, Ib2 and IIa cervical cancer who underwent a procedure for sentinel lymph node identification. The study was conducted from May 2006 to December 2007 and was described in two articles. The first article was about a study of sentinel lymph node detection in cervical cancer using a combination of patent blue dye and technetium99m. It assessed the agreement between preoperative lymphoscintigraphy and intraoperative lymphatic mapping with a gamma probe. The second article focused on the evaluation of changes in pulse oximetry readings in patients undergoing surgery after patent blue injection. Results: In the first article, at least one sentinel lymph node was identified in 83.13% of the patients and the most frequent site for finding sentinel lymph nodes was the external iliac chain. The sensitivity, specificity, positive predictive value and negative predictive value were 80%, 100%, 100% and 97.67% respectively on histopathology examination of frozen biopsy. In addition, it was observed that preoperative lymphoscintigraphy detected a substantially lower number of sentinel lymph nodes when compared to intraoperative lymphatic mapping with a gamma probe. In the second study, only one patient presented with an anaphylactic reaction. Thirteen patients showed a decrease in pulse oximetry readings (less than 96% saturation) after patent blue injection into the cervix, which lasted an average of five minutes and had no clinical repercussions. There was a borderline association between this decline in oxygen saturation values and tumors that were larger and located around the external cervical os. Conclusions: It was concluded that a combination of patent blue dye and technetium99m demonstrated excellent results in the detection of sentinel lymph nodes. Preoperative lymphoscintigraphy offers no advantage in relation to intraoperative lymphatic mapping with patent blue dye and technetium99m. There were no clinical repercussions due to lower oxygen saturation values. These changes correlated with tumors that were larger and located around the external cervical os, although the significance of this correlation was borderline. / Doutorado / Ciencias Biomedicas / Doutor em Tocoginecologia
104

Extratumoral effects of highly aggressive prostate cancer / Aggressiv prostatacancer : tidig påverkan i extratumoral vävnad

Strömvall, Kerstin January 2017 (has links)
Prostate cancer (PC) is the most common cancer in Sweden. Most patients have slow growing tumors that will not cause them any harm within their lifetime, but some have aggressive tumors and will die from their disease. The ability of current clinical practice to predict tumor behavior and disease outcome is limited leading to both over- and undertreatment of PC patients. The men who die from their disease are those that develop metastases. It is therefore of great value to find better and more sensitive prognostic techniques, so that metastatic spread can be detected (or predicted) at an early time point, and so that appropriate treatment can be offered to each subgroup of patients. The aim of this thesis was to investigate if, and by what means, highly aggressive prostate tumors influence extratumoral tissues such as the non-malignant parts of the prostate and regional lymph nodes (LN), and also if any of our findings could be of prognostic importance. Gene- and protein expression analysis were the main methods used to address these questions. Our research group has previously introduced the expression Tumor Instructed (Indicating) Normal Tissue (TINT), and we use the term TINT-changes when referring to alterations in non-malignant tissue due to the growth of a tumor nearby or elsewhere in the body. In the Dunning rat PC-model we found that MatLyLu (MLL)-tumors, having a high metastatic ability, caused pre-metastatic TINT-changes that differ from those caused by AT1-tumors who have low metastatic ability. Prostate-TINT surrounding MLL-tumors had elevated immune cell infiltration, and gene ontology enrichment analysis suggested that biological functions promoting tumor growth and metastasis were activated in MLL- while inhibited in AT1-prostate-TINT. In the regional LNs we found signs of impaired antigen presentation, and decreased quantity of T cells in the MLL-model. One of the downregulated genes in the MLL-LNs was Siglec1 (also known as Cd169), expressed by LN resident macrophages that are important for antigen presentation. When examining metastasis-free LN tissue from PC patients we found CD169 expression to be a prognostic factor for PC-specific survival, and reduced expression was linked to an increased risk of PC-specific death. Some of our findings in prostate- and LN-TINT could be seen already when the tumors were very small suggesting that differences in TINT-changes between tumors with different metastatic capability can be detected early in tumor progression. However, before coming of use in the clinic more research is needed to better define a suitable panel of prognostic TINT-factors as well as the right time window of when to use them. / Populärvetenskaplig sammanfattning Prostatacancer är den i särklass vanligaste cancerformen hos män i Sverige. De flesta patienter har en mycket långsamt växande tumör som inte orsakar dem några större besvär under deras livstid, men enbart i Sverige dör ca 2500 patienter/år av sjukdomen. Det är först vid uppkomst av metastaser som sjukdomen blir dödlig. Befintliga diagnos- och prognosmetoder är otillräckliga när det gäller att uppskatta och förutse tumörens aggressivitet och risk för att bilda metastaser. Detta gör att vissa patienter inte får tillräcklig behandling eller behandlas försent medan andra behandlas i onödan. Behovet av förbättrad diagnostik är därför stort. Om vi kan hitta markörer för potentiellt metastaserande sjukdom, och i bästa fall också behandla innan metastaser uppstår, skulle det förbättra chansen för överlevnad markant. För att kunna växa och spridas behöver en tumör inte bara förbereda närliggande vävnader utan förmodligen hela kroppen. Vår hypotes är att potentiell dödliga tumörer sannolikt är bättre på detta än mer ofarliga. Man vet från studier av andra cancerformer att farliga tumörer orsakar förändringar i det organ dit cancern senare sprids. Dessa förändringar sker för att de tumörceller som senare anländer ska kunna överleva, och processen har fått namnet pre-metastatisk nisch. Bl.a. har man sett att immunsystemet hämmas och nybildning av kärl ökar. Det är vanligt att metastaser uppstår i närliggande lymfkörtlar innan uppkomst av metastaser i andra organ. Dock är väldigt lite känt om pre-metastatiska förändringar i lymfkörtlar eftersom den forskning som hittills är gjord främst har tittat på andra organ. Inom prostatacancer finns det förvånande få studier av premetastatiska nischer överhuvudtaget, och man vet därför inte om de alls förekommer eller vilka förändringar som i så fall sker. Vår grupp har tidigare myntat uttrycket TINT som står för Tumor Instructed (Indicating) Normal Tissue (TINT är ett engelskt verb som betyder färga) och syftar på förändringar i normal vävnad som inducerats av tumören, dvs. att tumörer färgar av sig på omgivningen. Det kan vara förändringar i normal vävnad nära tumören, som i det här fallet resten av prostatan, eller i vävnad långt ifrån tumören som till exempel regionala lymfkörtlar, lungor och benmärg. Syftet med det här avhandlingsarbetet var att undersöka TINT-förändringar inducerade av aggressiv cancer och se om dessa skiljer sig från TINT-förändringar inducerade av mindre farliga tumörer, samt att utvärdera om någon TINT-förändring skulle kunna användas för att prognostisera vilka patienter som har hög risk att få metastaser. Vi har använt oss av en prostatacancer-modell i råtta där vi analyserat genoch proteinuttryck i pre-metastatiska regionala lymfkörtlar, tumörer och prostata-TINT (dvs. prostatavävnad utanför tumören). TINT-förändringar inducerade av MatLyLu (MLL), en tumör med hög metastaserande förmåga, jämfördes mot TINT-förändringar inducerade av AT1, en snabbväxande tumör men med låg förmåga att bilda metastaser. Vi kunde vi se flera skillnader mellan modellerna. Genuttrycket i MLL-prostata-TINT indikerade en aktivering av cellulära funktioner som visat sig stimulera tumörväxt och spridning såsom celldelning, viabilitet, migration, invasion, och angiogenes (nybildning av kärl). I AT1-prostata-TINT var genuttrycket kopplat till samma funktioner men verkade istället inhibera dessa. Genom att titta på vävnaderna i mikroskop kunde vi se att MLL-tumörer rekryterade färre T-celler (som har en viktig funktion i immunsvaret mot tumören), men istället fler makrofager och granulocyter till både tumören och prostata-TINT (dessa typer av immunceller har visats kunna hjälpa tumörer att växa och sprida sig). MLL-tumörer hade också fler blodkärl och lymfkärl strax utanför tumören. I de regionala lymfkörtlarna från djur med MLL-tumörer visade genuttrycket tecken på försämrad antigenpresentation, samt immunhämning och/eller induktion av immuntolerans. Immuntolerans innebär att immuncellen inte längre reagerar mot det specifika antigen den blivit tolerant emot. Detta är vanligt förekommande hos individer med cancer och är ett sätt för tumören att undkomma immunförsvaret. I vävnadsprover av lymfkörtlarna kunde vi se färre antigenpresenterande celler, och liksom i tumörerna fanns det färre T-celler i MLL-modellen, något vi kunde se redan när tumörerna var väldigt små. CD169 är ett protein som bl.a. uttrycks av sinus-makrofager i lymfkörtlar. Dessa makrofager har en central funktion i att aktivera ett tumör-specifikt immunsvar. I råttmodellen kunde vi se att regionala lymfkörtlar från djur med MLL-tumörer hade lägre nivåer av CD169 än regionala lymfkörtlar från djur med AT1-tumörer, och då antalet sinus-makrofager visat sig ha prognostiskt värde i t.ex. tjocktarmscancer, ville vi se om det kunde vara så även i prostatacancer. Därför kvantifierade vi uttrycket av CD169 i metastasfria regionala lymfkörtlar från prostatacancerpatienter och såg att låga nivåer av CD169 medförde en ökad risk för att dö i prostatacancer. Sammantaget tyder resultaten på att MLL-tumören jämfört med AT1- tumören bättre lyckas förbereda omgivande vävnad för att gynna tumörväxt och spridning, både lokalt i prostatan men också längre bort från tumören i de regionala lymfkörtlarna. Våra fynd stämmer väl överens med aktuell tumörbiologisk forskning om hur tumörer påverkar sin omgivning. Något som inte visats tidigare är att miljön utanför tumören verkar skilja sig drastiskt beroende på tumörens metastaserande förmåga, samt att dessa skillnader går att se relativt tidigt under sjukdomsförloppet och förmodligen även långt bort från tumören. Vi har också visat att särskilt aggressiv prostatacancer verkar inducera en pre-metastatisk nisch i tumördränerande lymfkörtlar likt det som beskrivits i andra modellsystem och i andra cancertyper, men hittills inte i prostatacancer. Fler studier behövs för att bättre karaktärisera de förändringar som en potentiellt dödlig prostatacancer orsakar i andra vävnader, och för att ta reda på hur denna kunskap kan användas för att förbättra diagnostik och behandling.
105

Identification et caractérisation moléculaire et fonctionnelle des cellules tissulaires de l’immunité innée chez les patients atteints de maladies inflammatoires intestinales

Chapuy, Laurence 01 1900 (has links)
Les maladies inflammatoires intestinales (MII), maladie de Crohn (MC) et colite ulcéreuse (CU), représentent un problème de santé publique majeur en raison de leur prévalence, de leur chronicité et de l’absence de traitement curatif disponible. La physiopathologie de ces maladies implique des facteurs de prédisposition génétique, des facteurs environnementaux et une réponse anormale du système immunitaire. De par leur position à l’interface entre les facteurs environnementaux, les cellules épithéliales et les cellules de l’immunité adaptative, les cellules de l’immunité innée (phagocytes monocucléés (MNPs) et granulocytes) sont des acteurs importants dans l’initiation et le maintien de l’inflammation intestinale. Largement étudiés chez la souris, leur investigation chez l’humain restait parcellaire, souvent contradictoire dans le colon et rarement étudiée dans le ganglion mésentérique (MLN). Nous avons caractérisé par des méthodes de cytométrie de flux multi-couleurs, de cytométrie de masse (CyTOF) et de séquencage de l’ARN (total et à l’échelon de la cellule unique), les MNPs de la muqueuse colique et des ganglions mésentériques chez les patients atteints de MC et de CU. Nous avons également évalué la fonction des MNPs et des basophiles sur les réponses mémoires T CD4+ autologues tissulaires. Notre travail a mis en évidence des similitudes et des différences entre la MC et la CU, dans la distribution des MNPs et le profil de la réponse mémoire T CD4+ dans le colon et le ganglion. La sous-population de MNPs HLADR+SIRPα+CD14+CD64+CD163- qualifiée de monocytes inflammatoires, et non les macrophages HLADR+SIRPα+CD14+CD64+CD163+, s’accumule dans la muqueuse inflammatoire des patients atteints de MC et de CU, et promeut les réponses mémoires de type Th17 et Th17/Th1 d’une manière dépendante de l’IL-1β. La fréquence de cette population corrèle avec le score de sévérité endoscopique en MC. Cependant, la distribution des MNPs ganglionnaires diffère entre la MC et la CU. Nous montrons que, dans les ganglions des patients atteints de CU, les MNPs HLADR+SIRPα+CD14+CD64+ sont enrichis en cellules CD163+, qui incluent principalement des cellules ‘monocyte-like’ HLA-DRdim en plus de macrophages HLA-DRhi. Parmi les cellules dendritiques (DCs) HLADR+SIRPα+CD14-CD64-, les DCs plasmocytoides prédominent dans les deux MII, avec une fréquence supérieure en MC qu’en CU. Par ailleurs, l’IL-1β dans la MC et l’IL-12 dans la CU favorisent un profil pathogénique dans les lymphocytes T CD4+ (IFN-γ, TNF-α, GM-CSF, IL-6) de la muqueuse colique. Par sérendipité, nous avons aussi mis en évidence que l’IL-12 et les monocytes inflammatoires tissulaires induisent la production d’IL-8 par les lymphocytes T CD4+ mémoires de la muqueuse intestinale et des MLNs dans la CU mais pas dans la MC. Au cours de cette étude, nous avons également observé l’accumulation de basophiles, mais pas de mastocytes, dans la muqueuse colique et le MLN en MC et en CU, et montré qu’ils favorisaient également les réponses Th17 et Th17/Th1 et non Th1 dans les lymphocytes T CD4+ mémoires exprimant CCR7. En conclusion, la caractérisation des MNPs de la muqueuse intestinale et des MLNs dans les maladies inflammatoires intestinales (MII) permet de mieux appréhender la physiopathologie de la maladie, dans l’espoir d’optimiser la stratification des MII et de permettre ainsi une prise en charge thérapeutique personnalisée. / Crohn's disease (CD) and ulcerative colitis (UC), two common forms of inflammatory bowel disease (IBD), represent a major public health problem because of their prevalence, chronicity and lack of available curative treatment. The pathophysiology of these diseases involves predisposing genetic factors, environmental triggers, and a dysfunctional immune response. Innate immune cells, including mononuclear phagocytes (MNPs) and granulocytes, are important players in the initiation and maintenance of intestinal inflammation due to their position at the interface between the external environment, epithelium and adaptive immune cells. Although widely studied in mice, their investigation in humans remains fragmentary, often with contradictory findings reported in the colon, and they are rarely studied in the mesenteric lymph nodes (MLNs). MNPs from the colon and MLNs of patients with CD and UC were characterized by multi-color flow cytometry, mass cytometry (CyTOF) and RNA sequencing (bulk and single cell). The function of MNPs and basophils on autologous memory CD4+ T cell responses was also assessed. The results presented here highlight similarities and differences in the distribution of MNPs between CD and UC, and the profile of memory CD4+ T cell response in colon and MLNs. HLADR+SIRPα+CD14+CD64+CD163- MNPs, defined as inflammatory monocytes, but not HLADR+SIRPα+CD14+CD64+CD163+ macrophages, accumulated in the inflammatory mucosa of CD and UC patients, and promoted Th17 and Th17/Th1 memory responses in an IL-1β dependent manner. The frequency of this subpopulation correlated with endoscopic severity in CD. In contrast, the distribution of these two MNP populations in the MLNs differs between CD and UC. HLADR+SIRPα+CD14+CD64+ MNPs were enriched in CD163+ cells that predominantly included HLA-DRdim monocytes-like cells over HLA-DRhi macrophages in UC patients only. Among HLADR+SIRPα+CD14-CD64- dendritic cells (DCs), plasmocytoid DCs predominated in both UC and CD, with higher frequency in CD versus UC. IL-1β in CD and IL-12 in UC favor a pathogenic CD4+ T cell profile (IFN-γ, TNF-α, GM-CSF, IL-6 expression/production) in the colonic mucosa. It was also demonstrated that IL-12 and inflammatory tissue monocytes induced IL-8 production by memory CD4+ T cells in intestinal mucosa and MLNs of UC but not CD. In this study, it was also observed that basophils and not mast cells accumulated, in the colonic mucosa and MLNs of CD and UC patients, and favored Th17 and Th17/Th1, but not Th1, responses in CCR7+ memory CD4+ T cells. In conclusion, characterization of MNPs in the intestinal mucosa and MLNs of IBD patients contributes to a better understanding of IBD pathophysiology and opens avenues to optimize patient stratification, and thus, personalized treatment of IBD patients.
106

Rôle de CD47 dans l’induction de la tolérance in vivo

Gautier-Éthier, Patrick 08 1900 (has links)
La tolérance orale permet la modulation de la réponse immunitaire à l’égard des antigènes exogènes présents dans la lumière intestinale. Essentiels à l’établissement d’une relation symbiotique entre le système immunitaire et la flore intestinale, l’induction et le maintien de la tolérance orale reposent sur différents mécanismes immunologiques. Parmi eux, l’induction de cellules T régulatrices par les cellules dendritiques et de mécanismes apoptotiques. Or, la glycoprotéine membranaire CD47 est impliquée, en périphérie, dans ces mécanismes. Cependant, le rôle de CD47 dans la tolérance orale n’est pas connu. À l’aide d’un modèle murin déficient en CD47, nous avons démontré principalement, que l’absence de CD47 est associée à une diminution de 50 % de la proportion de cellules dendrites myéloïdes CD11b+CD103- retrouvées dans les ganglions mésentériques. Suite au transfert adoptif de cellules T antigènes spécifiques dans nos différents modèles expérimentaux, on a, aussi, observé une diminution de 45 % de leur niveau d’activation dans les ganglions mésentériques. Malgré les effets observés, le CD47 n’est pas impliqué dans l’induction d’une réaction de tolérance orale secondaire à l’administration intragastrique de fortes doses d’ovalbumine. Cependant, nous avons démontré que CD47 est impliquée au niveau de la migration des cellules dendritiques de la peau et de certaines sous-populations retrouvées dans les ganglions mésentériques. / Oral tolerance allows the modulation of the immune response against exogenous antigens present in the intestinal lumen. Essential to establish a symbiotic relationship between the immune system and intestinal flora, the induction and maintenance of oral tolerance rests on different immunological mechanisms. Among them, induction of regulatory T cells by dendritic cells and apoptotic mechanisms. However, the membrane glycoprotein CD47 is involved in the periphery of these mechanisms. However, the role of CD47 in oral tolerance is unknown. With a mouse model deficient in CD47, we showed mainly that the absence of CD47 is associated with a decrease of 50% in the proportion of myeloid dendritic cells CD11b+ CD103- found in the mesenteric lymph nodes. Following the adoptive transfer of antigen specific T cells in our experimental models, we also observed a decrease of 45% of their level of activation in mesenteric lymph nodes. Despite the observed effects, CD47 is not involved in the induction of oral tolerance response secondary to intragastric administration of high doses of ovalbumin. However, we have shown that CD47 is involved in the migration of dendritic cells of the skin and some sub-populations found in mesenteric lymph nodes.
107

Uticaj dubine invazije oralnog planocelularnog karcinoma na pojavu metastaza u limfnim čvorovima vrata / The effect of depth of tumor invasion on neck lymph node metastasis in patients with oral squamous cell carcinoma

Mijatov Ivana 22 November 2019 (has links)
<p>Oralni karcinom je po učestalosti &scaron;esta najče&scaron;ća maligna bolest u svetu čija incidenca varira u različitim geografskim područjima. Predstavlja 5% svih novootkrivenih malignih tumora godi&scaron;nje i čini 14% svih malignih tumora glave i vrata. Pod oralnim karcinom podrazumevamo planocelularni karcinom obzirom na činjenicu da on čini preko 90% malignih tumora oralne lokalizacije, dok se u manjem procentu javljaju drugi tumori (maligni tumori malih pljuvačnih žlezda, limfomi, mezenhimni tumori). Oralni karcinom podrazumeva karcinome koji se javljaju u sledećim anatomskim regijama: sluznici prednje 2/3 jezika, poda usta, obraza, gingivi gornje i donje vilice, retromolarnom trouglu, kao i sluznici mekog i tvrdog nepca. Najče&scaron;ća lokalizacija oralnog planocelularnog karcinoma je sluznica pokretnog dela jezika i poda usta. Oralni karcinom se če&scaron;će javlja kod mu&scaron;karaca (odnos mu&scaron;karci:žene je 3:1) verovatno zbog većeg procenta rizičnog pona&scaron;anja kod mu&scaron;karaca. Najče&scaron;će se javlja u &scaron;estoj i sedmoj deceniji života (medijana je 62 godine) iako se poslednjih godina sve če&scaron;će javlja kod mlađih od 45 godina. Faktori rizika za oboljevanje su dobro poznati. Na prvom mestu se izdvaja pu&scaron;enje duvana (značajna je dužina pu&scaron;enja, da li pacijent pu&scaron;i lulu ili cigaretu, da li žvaće duvan, kao i dužina trajanja apstinencije). Smatra se da je smrtnost kod oralnog karcinoma direktno povezana sa brojem popu&scaron;enih cigareta na dan. Preko 75% pacijenata sa oralnim karcinomom anamnestički daje podatak o prekomernoj upotrebi alkohola. Postoji sinergističko dejstvo alkohola i cigareta, dugotrajna ekspozicija ovim faktorima rizika dovodi do pojave &ldquo;polja kancerizacije&ldquo;, pojave genetske nestabilnosti i razvoja tumora. Kod oralnog planocelulranog karcinoma primećene su hromozomske abnormalnosti koje su rezultat o&scaron;tećenja DNK i uključuju promene genetskog materijala na hromozomima.Jedna od najče&scaron;ćih genetskih abnormalnosti kod oralnog planocelularnog karcinoma je mutacija r53 gena koji se nalazi na kratkom kraku hromozoma 17 i predstavlja tumor supresor gen. Planocelularni karcinom nije te&scaron;ko dijagnostikovati kada postane simptomatski. Pacijent se žali na bol, krvavljenje, otalgiju, otežano gutanje, smanjenje pokretljivosti jezika. Neretko je prvi simptom metastatski uvećan limfni čvor na vratu jer bolesnici ne primećuju ili ignori&scaron;u oralnu patologiju. Dijagnoza oralnog karcinoma se postavlja na osnovu detaljno uzete anamneze, kliničkog pregleda i patohistolo&scaron;ke verifikacije. Oralni planocelularni karcinom se javlja u tri klinike forme: egzofitična, endofitična i infiltrativna. Zlatni standard za dijagnozu oralnog karcinoma je biopsija i patohistolo&scaron;ka verifikacija, pri čemu se može primeniti &bdquo;punch&ldquo; biopsija, inciziona biopsija ili eksciziona biopsija kod manjih promena. TNM &bdquo;staging&ldquo; sistem AJCC (American Joint Committee on Cancer) se danas standardno koristi za klinički &bdquo;staging&ldquo; oralnog karcinoma i bazira se na podacima dobijenim kliničkim pregledom i &bdquo;imaging&ldquo; metodama. Sam &bdquo;staging&ldquo; je bitan kako zbog komunikacije među lekarima koji učestvuju u lečenju bolesnika tako i zbog standardizacije prognoze. T stadijum označava veličinu primarnog tumora, N stadijum označava regionalnu nodalnu zahvaćenost dok M stadijum prikazuje prisustvo udaljenih metastaza. Terapija patohistolo&scaron;ki dokazanog oralnog karcinoma zahteva multidisciplinarni pristup. Osnova terapije oralnog planocelularnog karcinoma je hirur&scaron;ko lečenje koje podrazumeva ablativno i rekonstruktivno hirur&scaron;ko lečenje. Osnovni princip ablativne hirurgije kod oralnog karcinoma je resekcija primarnog tumora sa najmanje 1cm negativnim hirur&scaron;kim marginama. Pored ablacije tumora hirur&scaron;ko lečenje podrazumeva i uklanjanje regionalnih limfnih čvorova vrata. Cilj disekcije vrata je da se kod klinički evidentnih metastaza iste uklone (terapijska disekcija) ili da se uklone okultne metastaze koje su klinički neevidentne (elektivna disekcija). Oralni planocelularni karcinom spada u tumore sa visokom stopom smrtnosti, većom nego &scaron;to je kod limfoma, laringealnog karcinoma, karcinoma testisa i endokrinih karcinoma. Stopa petogodi&scaron;njeg preživljavanja je direktno povezana sa veličinom tumora, prisustvom metastaza u regionalnim limfnim čvorovima i prisutvom udaljenih metastaza. Prosečno trogodi&scaron;nje preživljavanje bolesnika sa oralnim karcinomom je 52% dok je prosečno petogodi&scaron;nje preživljavanje oko 39% i ove stope se nisu mnogo menjale tokom godina bez obzira na nova saznanja i nove pristupe lečenju oralnog planocelulanog karcinoma. Ciljevi istraživanja su da se utvrdi da li postoji korelacija debljine OPK izmerene kompjuterizovanom tomografijom i svetlosnim mikroskopom, da li dubina invazije OPK i volume tumora mogu biti prediktivni faktor za razvoj regionalnih cervikalnih metastaza kod oralnog planocelularnog karcinoma. Istraživanje je uključilo 65 konsekutivnih bolesnika oba pola lečenih od oralnog karcinoma na Klinici za maksilofacijalnu hirurgiju Kliničkog centra Vojvodine. Dijagnoza oralnog karcinoma je postavljena na osnovu anamneze, kliničkog pregleda i biopsije. U sklopu TNM &bdquo;staging&ldquo;-a bolesnika načinjen je pregled glave i vrata i grudnog ko&scaron;a kompjuterizovanom tomografijom (CT) na osnovu kog smo dobili podatak o dimenzijama tumora. Na osnovu kliničkog nalaza i analize CT nalaza planiralo se operativno lečenje u skladu sa bolesnikovim TNM statusom. Postoperatativni patohisto&scaron;ki preparati je pregledan od strane istog patologa. Parametri koji će su određivani su sledeći: 1. Veličina tumora (2 dimenzije) izmerene na osnovu CT pregleda izražene u cm 2. Debljina tumora izmerena na osnovu CT pregleda izražena u cm 3. Veličina tumora (2 dijametra) na makroskopskom preparatu izražena u cm 4. Debljina tumora na mikroskopskom preparatu izmerena svetlosnim mikroskopom izražena u cm 5. Dubina invazije tumora na mikroskopskom preparatu izmerena svetlosnim mikroskopom izražena u mm 6. Volumen tumora koji se izračunavao prema formuli: VT=&pi;/6 x maksimalni dijametar tumora A x minimalni dijametar tumora B x dubina invazije tumora i izražava se u cm&sup3; 7. Broj metastatski izmenjenih limfnih čvorova u disekatu vrata 8. Ukupan broj patohistolo&scaron;ki ispitanih limfnih čvorova u disekatu vrata Nakon prikupljanja planiranog materijala urađena je statistička obrada podataka. Statistička analiza podataka je uključila metode deskriptivne statistike (srednja vrednost, standardna devijacija, učestalost), kao i standardne parametrijske i neparametrijske testove za komparacije dve grupe (Studentov T test, Mann&ndash;Whitney U test, hikvadrat test). U fazi statističke analize međusobnih uticaja i povezanosti prikupljenih podataka kori&scaron;ćen je Pearsonov test korelacije. Sva testiranja sprovedena su na nivou statističke značajnosti p&lt;0,05. REZULTATI: Istraživanje je obuhvatilo 65 bolesnika, od kojih je 82% bilo mu&scaron;kog pola prosečne starosti 59 godina. 83% bolesnika su se izja&scaron;njavali kao pu&scaron;ači, dok je 69% bolesnika navelo da redovno koristi alkohol. Svim pacijentima je tokom hirur&scaron;kog lečenja OPK rađena disekcija vrata i to najče&scaron;čće selektivna disekcija vrata (91%). Kod 30 bolesnika je utvrđeno postojanje cervikalnih regionalnih metastaza na operativnom preparatu te su bolesnici podeljeni u dve grupe: sa prisustvom i bez prisustva metastaza u limfnim čvorovima vrata. Utvrđeno je da se ove dve grupe statistički značajno razlikuju u dubini invazije tumora i volumenu tumora. Utvrđeno je takođe da postoji statistički značajna korelacija između debljine tumora izmerene CT pregledom i debljine tumora izmerene svetlosnim mikroskopom. Dokazano je da dubina invazije tumora veća od 7mm i zapremina tumora veća od 4cm&sup3; predstavljaju prediktivni faktor za pojavu regionalnih cervikalnih metastaza. ZAKLjUČAK: Na osnovu istraživanja izvedeni su zaključci koji ukazuju na to da postoji statistički značajna korelacija između debljine tumora OPK izmerene CTpregledom i svetlosnim mikroskopom te se debljina tumora izmerena CT pregledom može koristiti za planiranje operativnog zahvata prilikom lečenja OPK. Dubina invazije tumora veća od 7mm i volumen tumora veći od 4 cm&sup3; predstavljaju prediktivni faktor za pojavu nodalnih cervikalnih metastaza te su značajni za određivanje stadijuma bolesti.</p> / <p>Oral cancer is the sixth most common malignant disease in the world which incidence varies based on geographic area. It represents 5% of all newly discovered malignant tumors annually and constitutes 14 % of all malignant tumors of head and neck. Squamous cell carcinoma is considered to be a type of oral cancer because more than 90 % of malignant tumors that occur in oral cavity are squamous cell carcinomas while other tumors (malignant tumor of minor salivary gland, lymphoma, sarcoma) rarely occur. Oral cancer is the cancer found in the following anatomic regions: mucosa of front two-thirds of the tongue, the floor of the mouth, cheeks, upper and lower gingiva, retromolar trigone as well as&nbsp; mucosa of soft and hard palates. Oral squamous cell carcinoma is most commonly localized in mucous membrane of the movable part of the tongue and floor of the mouth. Men are more affected than women (male to female ratio is 3:1) probably because of men&rsquo;s riskier behavior. It is most commonly diagnosed in the sixth and seventh decade of life (the median is 62 years old) although it has been diagnosed in patents younger than 45 in recent years. Risk factors of oral squamous cell carcinoma are well known. The major factor is tobacco smoking (the period of smoking is significant, it is also important to consider whether a patient smokes a pipe or cigarette, whether he/she chews tobacco as well as the period of abstinence). The mortality rate is believed to be directly related to the number of cigarettes smoked a day. An excessive use of alcohol has been reported in over 75% of patients with oral cancer. There is a synergistic effect of alcohol and cigarette consumption and long-term exposure to these risk factors results in &lsquo;field of cancerization&rsquo;, genetic instability and tumor development. Chromosome abnormalities, which are caused by DNA damage and include the change in genetic material of chromosomes, have been reported in patients with oral squamous cell carcinoma. One of the most common genetic abnormalities in patients with oral squamous cell carcinoma is a mutation of р53 gene which is located on a short arm of chromosome 17 and represents a tumor suppressor gene. Oral squamous cell carcinoma is not difficult to diagnose when it becomes symptomatic. The patient complains of pain, bleeding, otalgia, swallowing difficulties, decreased tongue mobility. The first symptom is rarely metastatic lymph node on the neck because patients either do not notice or ignore oral pathology. The oral cancer is diagnosed based on the detailed anamnesis, physical examination and pathohistological verification. The oral squamous cell carcinoma occurs in three clinical forms: exophytic, endophytic and infiltrative form. The gold standard for diagnosis of oral cancer is biopsy and pathohistological verification. However, in case of smaller changes, punch biopsy, incisional and excisional biopsies can also be applied. ТNМ staging system of AJCC (American Joint Committee on Cancer) is nowadays used for clinical staging of oral cancer and it is based on the data acquired by clinical examination and imaging methods. Not only is the staging itself important for communication between the doctors involved in treatment, but it is also important for standardization of prognosis. Т describes the size of primary tumor, N describes regional nodal spread and М describes distant metastasis. The treatment of histopathologically proven oral cancer requires multidisciplinary approach. The main treatment of oral squamous cell carcinoma is surgical treatment which involves ablative and reconstructive surgical treatment. The basic principle of ablative surgery for oral cancer is the resection of primary tumor with at least 1 cm negative surgical margins. Apart from tumor ablation surgical treatment also involves removal of regional lymph nodes on the neck. The aim of neck dissection is to remove clinically evident metastasis (therapeutic dissection) or to remove occult metastasis that are not clinically evident (elective dissection). The oral squamous cell carcinoma is the cancer with high mortality rate. The mortality rate is higher than the mortality rate for lymphoma, laryngeal cancer, testicular cancer and endocrine cancer. The five-year survival rate is directly related to the size of the tumor, presence of metastasis in regional lymph nodes and distant metastasis. The average three-year survival rate of the patients with oral cancer is 52% and the average five-year survival rate is 39%. These rates have not changed a lot over the years regardless of new knowledge and approaches in treatment of oral squamous cell carcinoma. The aims of the study are to determine whether there is a correlation between the depth of invasion of oral squamous cell carcinoma determined by computed tomography and light microscope and whether the invasion depth of OSCC and tumor volume can be predictive factors of development of regional cervical metastases in case of oral squamous cell carcinoma. The study covered 65 consecutive patients of both sexes who received treatment for oral cancer at the Clinic for Maxillofacial Surgery of the Clinical Center of Vojvodina. The diagnosis of oral cancer was established based on the anamnesis, physical examination and biopsies. The TNM &lsquo;staging&rsquo; of the cancer involved the examination of the patient&rsquo;s head and thorax by computed tomography (CT) which enabled us to obtain reliable data about the tumor size. After obtaining clinical findings and CT results, the patients&rsquo; treatment was planned based on their TNM status. A postoperative histopathological examination was performed by the same pathologist and the following parameters were determined: 1. Tumor size (2 dimensions) measured by CT and expressed in cm 2. Tumor thickness measured by CT and expressed in cm 3. Tumor size (2 diameters) on microscopic device and expressed in cm 4. Tumor thickness on microscopic device measured by light microscope and expressed in cm 5. Depth of tumor invasion on microscopic device measured by light microscope and expressed in cm 6. Tumor volume calculated based on the following formula: VT=&pi;/6 x maximum tumor diameter А x minimum tumor diameter B x depth of tumor invasion and expressed in cm&sup3; 7. The number of metastatic lymph nodes in the neck dissection 8. Total number of pathohistologically tested lymph nodes in the neck dissection. Upon collecting the planned material, statistical analysis of all data was carried out. The statistical analysis included the methods of descriptive statistics (mean value, standard deviation, frequency) and standard parametric and nonparametric tests for comparison of two groups (Student&rsquo;s T test, Whitney U test, chi-square test). The Pearson&rsquo;s Test of Correlation was used in the phase of statistical analysis of interaction effects and correlation of obtained data. All tests were performed at the level of statistical significance of p&lt;0.05. RESULTS: The study covered 65 patients, out of which 82% were male patients aged 59. 83% of patients said they smoked and 69% of patients stated that they consumed alcohol regularly. A neck dissection was performed in all patients during surgical treatment of OSCC and it was selective neck dissection (91%). Cervical regional metastasis was found in 30 patients so they were divided into two groups: the group of patients who had metastasis in the lymph nodes and the group of patients with no metastasis in lymph nodes of the neck. It was determined that there was a statistically significant difference in depth of invasion and tumor volume between these two groups. The statistically significant difference was also determined between the thickness of tumor measured by CT and thickness of tumor measured by light microscope. Moreover, the depth of invasion of tumor greater than 7mm and volume of tumor greater than 4cm&sup3; were proven to represent a predictive factor of development of regional cervical metastasis. The study results show that there is a statistically significant correlation between the thickness of OSCC tumor measured by CT and the thickness measured by light microscope, so the thickness of tumor measured by CT can be used for planning the surgery during the treatment of OSCC. The depth of tumor invasion greater than 7 mm and tumor volume greater than 4 cm&sup3; represent a predictive factor of development of cervical metastasis, which means that they are significant for determining the stage of disease.</p>
108

Eine prospektive Studie zur operativen Therapie des Beinlymphödems / Microsurgical therapy of lymphedema of the leg – a prospective study

Weiß, Sophia Magdalena 14 January 2020 (has links)
No description available.
109

Workflowanalyse Neck Dissection - monozentrische Betrachtung des chirurgischen Vorgehens im Interoperateur-Vergleich

Krempel, Annika 11 August 2015 (has links)
Die Kopf-Hals-Region ist eine der anatomisch kompliziertesten Regionen und enthält et- wa 300 Lymphknoten, die innerhalb eines komplexen Lymphgefäßsystems miteinander in Verbindung stehen. Die meisten Plattenepithelkarzinome der oberen Luft- und Speise- wege sind potentiell heilbar, aber sie metastasieren früh in die regionalen zervikalen Lymphknoten. Der Status dieser Lymphknoten ist der signifikanteste prognostische Faktor in der Therapie der Kopf-Hals-Tumoren. Die Neck Dissection, englisch für „Halsausräu- mung“, wird auch im deutschsprachigen Raum so genannt und ist der Standard der chir- urgischen Behandlung. Die vorliegende monozentrische Studie untersucht erstmals mittels Workflowanalyse ei- ne Serie von Neck dissections (ND) im Interoperateur-Vergleich und zielt auf die quali- tätsrelevante Erfassung der Operationssystematik ab. Von Januar bis Dezember 2011 wurden an einer onkologisch ausgerichteten HNO-Univer- sitätsklinik 42 selektive NDs (SND) und modifiziert radikale NDs (MRND) bei 5 unter- schiedlichen Operateuren mit der Workflowaufnahmesoftware s.w.an-Editor systemati- siert kodiert und vergleichend ausgewertet. Die Operateure variierten in ihrer Operationserfahrung mit Neck dissections zwischen 1- 17 Jahren und führten im Untersuchungszeitraum 19-76 NDs durch. Die Gesamtpräpara- tionszeit (15min. (2-48)) korrelierte negativ mit der Anzahl der jährlich durchgeführten NDs (p<.033). Bei der Dauer der Entfernung der einzelnen Lymphknotenpakete (33min. (10-81)) ergab sich eine negative Korrelation mit der jeweiligen Erfahrung des Opera- teurs (p<.001). 63 Als bevorzugte Reihenfolge der entfernten Level zeigte sich die Chronologie: 3-2A-(2B)- 5-4-(1). Diese variierte trotz „Schule des Hauses“ signifikant. Bei SNDs ergab sich eine Korrelation (p<.038) zwischen Erfahrung und Befolgung dieser Reihenfolge. Die Summe der entfernten Lymphknoten im histopathologischen Präparat gesamt (17 (0- 29)) sowie pro Level (3,8 (0-11)) zeigte keinen signifikanten Unterschied in Abhängigkeit von Erfahrung, Anzahl der 2011 durchgeführten NDs, befolgter Chronologie und Dauer der Operation. Trotz signifikanter Unterschiede bei den Operateuren im operativen Vorgehen fanden sich keine signifikanten Unterschiede in Gesamtsumme der entnommenen Lymphknoten- zahl. Die Workflowanalyse hilft, die Operationssystematik zu erfassen und damit bei wechselnden Operateuren einen Standard zu definieren.:1.1. KOPF-HALS-TUMOREN 1.2. ÄTIOLOGIE UND RISIKOFAKTOREN 1.3. EPIDEMIOLOGIE 1.4. KLINIK 1.5. DIAGNOSTIK 1.6. HISTORISCHER ÜBERBLICK 1.6.1. ANFÄNGE DER CHIRURGIE 1.6.2. ENTWICKLUNG DER STRAHLENTHERAPIE 1.6.3. RADIKALE NECK DISSECTION 1.6.4. FUNKTIONELLE ODER MODIFIZIERT RADIKALE NECK DISSECTION 1.6.5. SELEKTIVE NECK DISSECTION 1.6.6. NOMENKLATUR DER LYMPHKNOTEN-LEVEL 1.6.7. NOMENKLATUR DER NECK DISSECTION 1.7. THERAPIE 1.7.1. STRAHLENTHERAPIE 1.7.2. NECK DISSECTION 1.7.3. CHEMOTHERAPIE 1.8. AKTUELLEENTWICKLUNGEN 1.8.1. ENTWICKLUNGEN IN DER DIAGNOSTIK 1.8.2. ENTWICKLUNGEN DES CHIRURGISCHEN VORGEHENS 1.9. KOMPLIKATIONEN 1.10. PROGNOSE 2. AUFGABENSTELLUNG 3. MATERIAL UND METHODEN 3.1. PATIENTEN 3.2. DATENERHEBUNG 3.3. EIN- UND AUSSCHLUSSKRITERIEN DER ERHOBENEN DATEN 3.4. STATISTISCHE METHODEN II 4. ERGEBNISSE 4.1. GESAMTKOLLEKTIV 4.1.1. PATIENTENGUT 4.1.2. EINTEILUNG DER OPERATION IN PHASEN 4.1.3. EINTEILUNG DER DATEN NACH KOMPLEXITÄT DER OPERATION 4.2. OPERATEURE IM VERGLEICH 4.2.1. ERFAHRUNG UND ROUTINE DER OPERATEURE 4.2.2. GESAMTDAUER DER OPERATION 4.2.3. ANZAHL DER DURCHGEFÜHRTEN ARBEITSSCHRITTE 4.2.4. KORRELATION ZWISCHEN ERFAHRUNG SOWIE ROUTINE DER OPERATEURE UND DAUER DER OPERATION 4.3. LYMPHKNOTEN IM FOKUS 4.3.1. CHRONOLOGIE DER LYMPHKNOTENENTNAHME 4.3.2. HISTOPATHOLOGIE 5. DISKUSSION 5.1. GESAMTKOLLEKTIV 5.1.1. PATIENTENGUT 5.1.2. EINTEILUNG DER OPERATION IN PHASEN 5.1.3. EINTEILUNG DER DATEN NACH KOMPLEXITÄT DER OPERATION 5.2. OPERATEURE IM VERGLEICH 5.2.1. ERFAHRUNG UND ROUTINE DER OPERATEURE 5.2.2. GESAMTDAUER DER OPERATION 5.2.3. ANZAHL DER DURCHGEFÜHRTEN ARBEITSSCHRITTE 5.2.4. KORRELATION ZWISCHEN ERFAHRUNG SOWIE ROUTINE DER OPERATEURE UND DAUER DER OPERATION 5.3. LYMPHKNOTEN IM FOKUS 5.3.1. CHRONOLOGIE DER LYMPHKNOTENENTNAHME 5.3.2. HISTOPATHOLOGIE 5.4. SCHLUSSFOLGERUNG 6. BIBLIOGRAFIE
110

Competing Mortality Contributes to Excess Mortality in Patients with Poor-Risk Lymph Node-Positive Prostate Cancer Treated with Radical Prostatectomy

Fröhner, Michael, Scholz, Albrecht, Koch, Rainer, Hakenberg, Oliver W., Baretton, Gustavo B., Wirth, Manfred P. January 2012 (has links)
Background: Factors predicting survival in men with lymph node-positive prostate cancer are still poorly defined. Patients and Methods: 193 prostate cancer patients with histopathologically proven lymph node involvement with a median follow-up of 7.3 years were studied. 94% of patients received immediate hormonal therapy. Kaplan-Meier curves were calculated to evaluate overall survival rates and compared with the log-rank test. Cumulative disease-specific and competing mortality rates were calculated by competing risk analysis and compared with the Pepe-Mori test. Cox proportional hazard models were used to determine the independent significance of predictors of all-cause mortality. Results: Age (70 years or older vs. younger), Gleason score (8–10 vs. 7 or lower) and the number of involved nodes (3 or more vs. 1–2) were identified as independent predictors of all-cause mortality. When patients with 0–1 of these risk factors were compared with those with 2–3 risk factors, all-cause (rates after 10 years 21% vs. 71%, p < 0.0001), disease-specific (12 vs. 37%, p = 0.009) and competing mortality (9 vs. 33%, p = 0.02) differed significantly. Conclusions: Some of the excess mortality in patients with poor-risk lymph node-positive prostate cancer may be attributed to increased competing mortality, possibly caused by an interaction between comorbid diseases and hormonally treated persistent or progressive prostate cancer. / Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.

Page generated in 0.0323 seconds